Skip to Content

Eli Lilly and Co LLY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Eli Lilly Posts Strong Q4 as Pipeline Advancements Support Robust Long-Term Growth Outlook

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Eli Lilly reported strong fourth-quarter results slightly ahead of our earnings projection, but we don’t expect any major fair value estimate changes based on the minor outperformance. The strong operating results help complement one of the strongest developing drug pipelines in the industry, reinforcing our wide moat rating.

Read Full Analysis

Company Profile

Business Description

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact
Lilly Corporate Center
Indianapolis, IN, 46285
T +1 317 276-2000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Classic Growth
Employees 19,500

Related